GlassScriptPhysician profile
Ihtesham Qureshi
NPI 1275989543
$2,456.29
in general payments reported to CMS, 2019-2025
31 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $97.61 · 2022: $492 · 2023: $526 · 2024: $733 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.38 | 2022-2025 | |
| Lilly USA, LLC | $230.65 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Neurocrine Biosciences, INC. | $153.28 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $152.70 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $119.84 | 2019 | |
| Amgen INC. | $115.26 | 2022-2023 | Aimovig |
| Pfizer INC. | $96.24 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $82.59 | 2022-2024 | |
| Sk Life Science, INC. | $76.33 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $58.02 | 2023-2025 | Nuplazid, Daybue |
| Ge Healthcare | $53.17 | 2022-2024 | |
| Greenwich Biosciences, INC. | $50.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.51 | 2024-2025 | |
| Livanova USA, INC. | $47.44 | 2021 | |
| Celgene Corporation | $45.99 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $44.59 | 2024-2025 | Crexont, Rytary |
| Argenx US, INC. | $39.32 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.52 | 2025 | Caplyta |
| Biogen, INC. | $35.22 | 2024-2025 | Tysabri, Vumerity |
| Alkermes, INC. | $32.08 | 2025 | Aristada, Lybalvi |
| Ceribell, INC. | $25.01 | 2024 | Pocket Eeg Device |
| Boston Scientific Corporation | $23.84 | 2024 | Watchman Access System |
| Sumitomo Pharma America, INC. | $19.54 | 2024 | Aptiom |
| Insightec,INC | $19.48 | 2022 | |
| Harmony Biosciences LLC | $17.47 | 2023 | Wakix |
| Teva Pharmaceuticals USA, INC. | $17.18 | 2024 | Austedo Xr |
| Ucb, INC. | $15.71 | 2024 | Zilbrysq |
| Kyowa Kirin, INC. | $15.60 | 2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $14.39 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2024 | Andexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihtesham Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.